Leupeptin, Microbial (Synonyms: Acetyl-L-leucyl-L-leucyl-L-argininal) |
カタログ番号GC10027 |
可逆性プロテアーゼ阻害剤
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 103476-89-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Leupeptin analysis [1]: | |
Preparation Method |
The concentration of Leupeptin, Microbial was calculated by enzyme inhibition assay using 50 pg of papain and 0.2 mM of N-benzoylL-arginine ethyl ester as the target protease and papain substrate, respectively. Enzyme reactions were carried out at 25 ℃ and pH 6.2. |
Applications |
Leupeptin, Microbial is a leucine-specific protease and a metalloprotease. |
Cell experiment [2]: | |
Cell lines |
MRC-C cell |
Preparation Method |
To investigate the effect of Leupeptin, Microbial on virus yield, MRC-C cultures in 35 mm dishes were infected by adsorption of virus from 0T ml concentrated suspension of HCV 229E for 1 h at 36 ℃. The cultures were washed twice and overlaid with 2 ml Eagle’s MEM plus 0.2% bovine serum albumin and 20 mm-HEPES buffer pH 7.4. Leupeptin, Microbial at a range of concentrations was added to the virus inoculum, to the maintenance medium and also to maintenance medium used to treat the cultures for 1 h before infection. After 24 h at 36 ℃ in air, the cells were scraped into the medium and disrupted by sonication. |
Reaction Conditions |
0.4 to l00 µg/ml for 25 h(1 h before infection to 24 h after infection) |
Applications |
The protease inhibitor Leupeptin, Microbial prevented multiplication of the human coronavirus strain 229E in cultures of MRC-C cells. |
Animal experiment [3]: | |
Animal models |
C57BL/6NCrl male mouse |
Preparation Method |
Mice received i.p. injections of 0.5 ml sterile Phosphate Buffered Saline or 0.5 ml PBS containing 9–40 mg/kg Leupeptin, Microbial hemisulfate. |
Dosage form |
0, 9, 18 36 and 40 mg/kg Leupeptin, Microbial; Intraperitoneal injection |
Applications |
Rate of LC3b accumulation after Leupeptin, Microbial treatment was greatest in the liver and lowest in spleen. |
References: [1]. Kim IS, Kim YB, et,al. Characterization of the leupeptin-inactivating enzyme from Streptomyces exfoliatus SMF13 which produces leupeptin. Biochem J. 1998 Apr 15;331 (Pt 2)(Pt 2):539-45. doi: 10.1042/bj3310539. PMID: 9531495; PMCID: PMC1219386. [2]. Appleyard G, Tisdale M. Inhibition of the growth of human coronavirus 229E by leupeptin. J Gen Virol. 1985 Feb;66 (Pt 2):363-6. doi: 10.1099/0022-1317-66-2-363. PMID: 3968542. [3]. Haspel J, Shaik RS, et,al. Characterization of macroautophagic flux in vivo using a leupeptin-based assay. Autophagy. 2011 Jun;7(6):629-42. doi: 10.4161/auto.7.6.15100. Epub 2011 Jun 1. PMID: 21460622; PMCID: PMC3127049. |
Leupeptin、Microbialは広範なセリンとシステインプロテアーゼ阻害剤です[1]。Leupeptin、Microbialは可逆性のプロテアーゼ阻害剤であり、35 nM、3.4 μM、6 nM、および72 nMのKi値を持つ牛トリプシン、ヒトプラスミナーゼ、牛脾臓カテプシンB、および再生人間カルトリプシンに作用します[7]。
プロテアーゼ阻害剤であるLeupeptin、Microbialは、MRC-C細胞の培養において人間コロナウイルス株229Eの増殖を抑制しました[3]。トリプシン様プロテアーゼの阻害作用により、Leupeptin、Microbialは基質菌糸体の発達を維持しますが、静止相培養中のLeupeptin、Microbialのタンパク分解によってトリプシン様プロテアーゼが活性化されるため、基質菌糸体が消化されて空気中菌糸体形成が促進されます[2]。またカルペイン阻害剤であるLeupeptin, Microbialは主にネオマイシンから毛細胞を保護しました[5]。 Leupeptinから得られた肝炎B表面抗原(HBsAg)は細胞懸濁液培養物を最大50%回復させました[6]。
Leupeptin、Microbialはマウスでよく耐容されました。 Leupeptin、Microbialは、全組織抽出物およびリソソーム濃縮部分(LE部分)においてLC3b-IIを用量依存的に有意に増加させました。 電子顕微鏡(EM)レベルでは、Leupeptin、Microbialは電子密度の高い小胞構造の蓄積を誘発しました[4]。
References:
[1]. Aoyagi T, Miyata S, et,al. Biological activities of leupeptins. J Antibiot (Tokyo). 1969 Nov;22(11):558-68. doi: 10.7164/antibiotics.22.558. PMID: 4243683.
[2]. Kim IS, Kim YB, et,al. Characterization of the leupeptin-inactivating enzyme from Streptomyces exfoliatus SMF13 which produces leupeptin. Biochem J. 1998 Apr 15;331 ( Pt 2)(Pt 2):539-45. doi: 10.1042/bj3310539. PMID: 9531495; PMCID: PMC1219386.
[3]. Appleyard G, Tisdale M. Inhibition of the growth of human coronavirus 229E by leupeptin. J Gen Virol. 1985 Feb;66 ( Pt 2):363-6. doi: 10.1099/0022-1317-66-2-363. PMID: 3968542.
[4]. Haspel J, Shaik RS, et,al. Characterization of macroautophagic flux in vivo using a leupeptin-based assay. Autophagy. 2011 Jun;7(6):629-42. doi: 10.4161/auto.7.6.15100. Epub 2011 Jun 1. PMID: 21460622; PMCID: PMC3127049.
[5]. Aoyagi T, Miyata S, et,al. Biological activities of leupeptins. J Antibiot (Tokyo). 1969 Nov;22(11):558-68. doi: 10.7164/antibiotics.22.558. PMID: 4243683.
[6]. Coffin AB, Williamson KL, et,al. Profiling drug-induced cell death pathways in the zebrafish lateral line. Apoptosis. 2013 Apr;18(4):393-408. doi: 10.1007/s10495-013-0816-8. PMID: 23413197; PMCID: PMC3627356.
[7]. Ganapathi TR, Sunil Kumar GB, et,al. Analysis of the limitations of hepatitis B surface antigen expression in soybean cell suspension cultures. Plant Cell Rep. 2007 Sep;26(9):1575-84. doi: 10.1007/s00299-007-0379-7. Epub 2007 May 30. PMID: 17534624.
Cas No. | 103476-89-7 | SDF | |
同義語 | Acetyl-L-leucyl-L-leucyl-L-argininal | ||
Chemical Name | 2-acetamido-N-(1-((5-((diaminomethylene)amino)-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-4-methylpentanamide | ||
Canonical SMILES | O=C(C(C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H])([H])N([H])C(C([H])([H])[H])=O)N([H])C(C(N([H])C(C([H])=O)([H])C([H])([H])C([H])([H])C([H])([H])/N=C(N([H])[H])/N([H])[H])=O)([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] | ||
Formula | C20H38N6O4.1/2H2SO4 | M.Wt | 493.6 |
溶解度 | ≥ 24.7mg/mL in DMSO, ≥ 20mg/mL in Water | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.0259 mL | 10.1297 mL | 20.2593 mL |
5 mM | 0.4052 mL | 2.0259 mL | 4.0519 mL |
10 mM | 0.2026 mL | 1.013 mL | 2.0259 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *